Navigation Links
Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
Date:1/6/2011

THE WOODLANDS, Texas, Jan. 6, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced data from a recently completed clinical trial and mechanistic study of a solid oral dose formulation for LX4211, a dual inhibitor of sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2).

Results from the study demonstrated that administration of a 300 mg solid oral tablet dose of LX4211, administered as two 150 mg tablets, significantly increased total GLP-1 (p=0.001), active GLP-1 (p=0.032) and PYY (p=0.004), important mediators of glycemic and appetite control as well as other metabolic parameters.  Notably, single doses of LX4211 produced rapid and significant improvement in post-prandial glucose (PPG) and fasting plasma glucose (FPG), consistent with results seen in the previous Phase 2 study. Pharmacokinetic and pharmacodynamic data from the study indicated that the solid oral formulation worked as well as or better than the liquid formulation on key parameters of hormonal release, PPG and FPG.  Lexicon plans to move the tablet formulation forward into a Phase 2b study in the second quarter of 2011.

"The significant elevations of GLP-1 levels observed in the study are particularly important given its established relevance in the treatment of diabetes," said Brian Zambrowicz, Ph.D., executive vice president and chief scientific officer.  "Newly observed in this study was the effect of LX4211 on increasing circulating levels of PYY.  We believe the rapid reduction in blood sugar levels after meals, the increase in GLP-1 and the increase in PYY are all associated with SGLT1 inhibition by LX4211 in the gastrointestinal tract."

PYY and GLP-1 are g
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
2. Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
3. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
4. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
5. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2010 Financial Results
6. Lexicon Pharmaceuticals Announces Reacquisition of All Rights to Symphony Icon Programs
7. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
8. Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
9. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
10. Lexicon to Present at BIO International Convention
11. Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... SAN JOSE, Calif. , Nov. 26, 2014 ... proprietary technologies to produce novel therapies for infectious ... Opal , M.D., an internationally recognized key opinion ... to the Company,s scientific advisory board. ... , Ph.D., stated, "We believe Dr. Opal,s extensive ...
(Date:11/26/2014)... CHARLOTTE, N.C. , Nov. 25, 2014  At ... San Antonio this October, KaVo Kerr Group ... Institute Technology Expo, offering attendees the opportunity to see ... to well-respected key opinion leaders deliver lectures on the ... Kerr Group products include the new DEXIS CariVu Caries ...
(Date:11/26/2014)... Calif. , Nov. 25, 2014 /PRNewswire/ ... company focused on the development of mobile ... accurate testing in hospital and pre-hospital settings, ... Organization (ISO) 13485:2003 certification.  The certification was ... one of the world,s leading certification bodies. ...
Breaking Medicine Technology:Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3Nanomix Receives ISO 13485:2003 Certification 2
... Neurologix, Inc. (OTC Bulletin Board: NRGX ... landmark, randomized, double-blind Phase 2 clinical trial of NLX-P101, ... were presented during a symposium at the 2nd World ... trial, Dr. Peter Lewitt, Director of the Parkinson,s Disease ...
... Oct. 1 Elekta recently launched ABAS ( ... Simultaneous Truth and Performance Level Estimation (STAPLE) algorithm ... standard for autosegmentation accuracy—deforms atlases of anatomy previously ... patient image, creating a new structure set fit ...
Cached Medicine Technology:New Details Presented at the World Parkinson Congress on Neurologix's Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease 2New Details Presented at the World Parkinson Congress on Neurologix's Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease 3New Details Presented at the World Parkinson Congress on Neurologix's Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease 4New Details Presented at the World Parkinson Congress on Neurologix's Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease 5New Details Presented at the World Parkinson Congress on Neurologix's Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease 6New Details Presented at the World Parkinson Congress on Neurologix's Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease 7Elekta Launches ABAS 2.0 Autosegmentation Software Used to Plan Radiation Therapy in Patients With Cancer 2
(Date:11/27/2014)... DressVe , the well-known trendy young women’s clothing retailer, ... during Nov. 29 – Dec. 3 2014. In the special ... to 90% off. In addition, free delivery is provided for ... http://www.dressve.com/ , Dresses that combine trendy styles and high ... personality and figure. The designers of DressVe.com know this point ...
(Date:11/27/2014)... November 28, 2014 Cyber Monday cannot ... Turks & Caicos. This boutique resort, ranked #1 ... announcing a few highly sought out openings before Christmas ... they are offering every seventh night complimentary if booked ... is having a January 2015 promotion where every fourth ...
(Date:11/27/2014)... Luciana Lagana and her husband Gregory ... feature film that received 9 awards at the 2014 Zed ... It is also an official selection of the 2014 PollyGrind ... cinematic career for James Noel, a young filmmaker who excels ... mystery, filmed in glorious black and white, watching Omadox will ...
(Date:11/27/2014)... "As a nurse I see patients ... urinary incontinence," said an inventor from Whiting, N.J. "I ... accessory to prevent leakage and keep them dry and ... leakage. This prevents stains on pants, skirts and bottoms, ... ensures that the individual has time to get to ...
(Date:11/27/2014)... News) -- Thanksgiving meals can pose a challenge for ... expert says. Many traditional Thanksgiving dishes -- such ... are gluten-free, but "when it comes to pies, stuffing, ... Dr. Anca Safta, director of the Gluten and Allergic ... in North Carolina, said in a center news release. ...
Breaking Medicine News(10 mins):Health News:DressVe.com Introduces Its 2014 Special Monday Sales To The Global Customers 2Health News:The Tuscany on Grace Bay, Top-Rated TripAdvisor Resort in the Turks & Caicos Islands, Offers Special Pre-Christmas & January 2015 Promotions! 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 3Health News:Expert Shares Gluten-Free Thanksgiving Tips 2
... amphetamine abuse in the Asia-Pacific region has hit high levels ... problem threatening Asia that is this big is a problem ... Australia as is the security of Australia in terms of ... the United Nations Office of Drugs and Crime told AFP. ...
... in building an extensive catalog of information about how ... ,This so-called "Connectivity Map" will be able to ... wrote in the latest issue of Science. ... published in the journal Cancer Cell, may accelerate the ...
... the count of consultants employed in Scotland's hospitals went ... British Medical Association has indicated that the replenishment hardly ... Service. From the recent figures published, it is evident ... NHS is inadequate to meet the growing demands. ...
... Scientists at the University of California, San Diego and ... by Bacillus thuringiensis, a bacterium sprayed// on crops by ... at treating hookworm infections in laboratory animals. ,Their ... the Proceedings of the National Academy of Sciences, could ...
... develop breast cancer in her life. But how much do ... cancer specialists from the University of Michigan Comprehensive Cancer Center ... And in some cases the fear paralyzes women and prevents ... treatment. ,Here, experts debunk some of the most ...
... common allergies like asthma, pollen and hayfever that afflict millions ... may occur indirectly due to too much cleanliness as it ... that have lived with humans for millions of years. As ... substances like grass pollen. ,This theory was exploited ...
Cached Medicine News:Health News:Genetic Map Reveals How Drugs Fight Diseases: Study 2Health News:Bacterial Protein Shows Promise in Treating Intestinal Parasites 2Health News:Bacterial Protein Shows Promise in Treating Intestinal Parasites 3Health News:16 Common Myths About Breast Cancer 2Health News:16 Common Myths About Breast Cancer 3Health News:16 Common Myths About Breast Cancer 4Health News:16 Common Myths About Breast Cancer 5
... automated, easy to operate and maintain. The ... by flexible snap-seal pockets which minimize the ... of the water. Offered in two-, four-, ... accommodate bags of various sizes. ThermoLine Thawing ...
Inquire...
... The Dengue virus belongs to the Flavavirus ... commonly throughout the tropics.,Symptoms of Dengue fever ... pain in the back and limbs, lymphadenopathy,maculopapular ... for professional use as an aid in ...
... This test device is intended ... of IgG and IgM antibodies ... serum. The test is used ... diagnosis of Dengue viral infection ...
Medicine Products: